Format for disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target company (TC)		Thyrocare Technologies Ltd			
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer		Arisaig Asia Fund Limited F.K.A. Arisaig Asia Consumer Fund Limited			
Whether the acquirer belongs to Promoter/Promoter group		No			
Name(s) of the Stock Exchange(s) where the shares of TC are Listed		BSE Ltd National Stock Exchange of India Ltd			
Details of the acquisition / disposal as follows		Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)	
	the disposal under consideration, holding of: Shares carrying voting rights	2,705,511	5.11%	5.11%	
b)	Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-	
c)	Voting rights (VR) otherwise than by equity shares	-	-	-	
d)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-	
e)	Total (a+b+c+d)	2,705,511	5.11%	5.11%	
Details	of acquisition /sale:				
a)	Shares carrying voting rights acquired/sold	-2,705,511	-5.11%	-5.11%	
b)	VRs acquired/sold otherwise than by equity shares	-	-	-	
c)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	-	-	-	
d)	Shares encumbered / invoked/released by the acquirer	-	-	-	
e)	Total (a+b+c+/-d)	-2,705,511	-5.11%	-5.11%	
After th	ne acquisition /sale, holding of:				
a)	Shares carrying voting rights	0	0.00%	0.00%	

b) Shares encumbered with the acquirer	-	-	-
c) VRs otherwise than by equity shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
e) Total (a+b+c+d)	0	0.00%	0.00%
Mode of acquisition / sale (e.g. open market / offmarket / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open market		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable.	20 June 2023		
Equity share capital/ total voting capital of the TC before the said acquisition / sale.	Rs. 52,930,043 (based on par value of Rs 1.00 and total issued shares of 52,930,043)		
Equity share capital/ total voting capital of the TC after the said acquisition / sale.	Rs. 52,930,043 (based total issued shares of 52,930,043)		
Total diluted share/ voting capital of the TC after the said disposal.	52,930,043		

- (*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.
- (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of Authorised Signatory

For and on behalf of Arisaig Partners (Asia) Pte Ltd, Investment Manager

Name: Gordon Yeo Tian Wee

Place: Singapore Date: 22 June 2023

ARISAIG PARTNERS

BSE Ltd

Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001 India 6 Lorong Telok, #02-01 Singapore 049019

+65 6532 3378

22 June 2023

Dear Sir

I am writing to notify that the accounts managed or advised by Arisaig Partners (Asia) Pte Ltd now holds a total of 207,407 shares in Thyrocare Technologies Ltd, equivalent to 0.3918% of the company's issued shares.

Enclosed herewith are the appropriate forms pursuant to Regulations 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations for your attention.

Yours sincerely

For and on behalf of Arisaig Partners (Asia) Pte Ltd, Investment Manager

Gordon Yeo

Authorized Signatory

Date: 22 June 2023

Format for disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target company (TC)		Thyrocare Technologies Ltd		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer		Acquirers (and holdings after disposal): • Arisaig Asia Fund Limited (0.00%) F.K.A. Arisaig Asia Consumer Fund Limited • Arisaig Next Generation Master Fund ICAV (0.1039%) • Segregated Mandate Account – Mercer QIF Fund PLC (0.2879%)		
Whether the acquirer belongs to Promoter/Promoter group		No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed		BSE Ltd National Stock Exchange of India Ltd		
Details of the acquisition / disposal as follows		Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
	the disposal under consideration, holding of: Shares carrying voting rights	3,152,162	5.9553%	5.9553%
b)	Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
c)	Voting rights (VR) otherwise than by equity shares	-	-	-
d)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e)	Total (a+b+c+d)	3,152,162	5.9553%	5.9553%
Details	of acquisition /sale:			
a)	Shares carrying voting rights acquired/sold	-2,944,755	-5.5635%	-5.5635%
b)	VRs acquired/sold otherwise than by equity shares	-	-	-
c)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	-	-	-
d)	Shares encumbered / invoked/released by the acquirer	-	-	-
e)	Total (a+b+c+/-d)	-2,944,755	-5.5635%	-5.5635%

After the acquisition/sale, holding of:				
a) Shares carrying voting rights	207,407	0.3918%	0.3918%	
b) Shares encumbered with the acquirer	-	-	-	
c) VRs otherwise than by equity shares	-	-	-	
 d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition 	-	-	-	
e) Total (a+b+c+d)	207,407	0.3918%	0.3918%	
Mode of acquisition / sale (e.g. open market / offmarket / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open market			
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable.	20 June 2023			
Equity share capital/ total voting capital of the TC before the said acquisition / sale.	Rs. 52,930,043 (based on par value of Rs 1.00 and total issued shares of 52,930,043)			
Equity share capital/ total voting capital of the TC after the said acquisition / sale.	Rs. 52,930,043 (based total issued shares of 52,930,043)			
Total diluted share/ voting capital of the TC after the said disposal.	52,930,043			

- (*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.
- (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of Authorised Signatory

For and on behalf of Arisaig Partners (Asia) Pte Ltd, Investment Manager

Name: Gordon Yeo Tian Wee

Place: Singapore Date: 22 June 2023